CD38 and CD58: A Gallant Savior in Under-Resourced Laboratories

Area of Science:

• Hematology
• Pediatric Oncology
• Immunophenotyping

Background:

• B-cell acute lymphoblastic leukemia (B-ALL) is a leading childhood cancer.
• Minimal residual disease (MRD) post-induction is a key prognostic factor in B-ALL.
• Current multiparametric flow cytometry for MRD detection is complex and requires expertise.

Purpose of the Study:

• To evaluate the utility of a simplified MRD "lite" panel for pediatric B-ALL.
• To compare the MRD "lite" panel against a standard multi-tube panel.
• To assess the feasibility of a cost-effective and universally applicable MRD detection method.

Main Methods:

• A single-tube MRD "lite" panel (CD38, CD10, CD34, CD19, CD45) was compared to a three-tube standard panel.
• MRD detection was performed on 25 pediatric B-ALL patients post-induction chemotherapy.
• Sensitivity, specificity, and inter-observer concordance were analyzed.

Main Results:

• The MRD "lite" panel demonstrated 100% sensitivity and 84.2% specificity compared to the standard panel.
• CD10, CD20, and CD200 expression aided in distinguishing MRD-positive from negative cases.
• 100% inter-observer concordance was achieved, indicating ease of interpretation.

Conclusions:

• The MRD "lite" panel is a sensitive and reliable tool for MRD detection in pediatric B-ALL.
• Its simplicity and cost-effectiveness enhance its applicability, especially in resource-limited settings.
• This approach offers a standardized and accessible alternative for MRD assessment.